CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer

Jacob J Orme¹, Emmanuel S Antonarakis^{2

3}, Scott M Dehm^{4

5

6}

Affiliations

¹ Department of Oncology, Mayo Clinic, Rochester, MN, USA.
² Division of Hematology, Oncology and Transplantation, University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA.
³ Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
⁴ Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. dehm@umn.edu.
⁵ Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. dehm@umn.edu.
⁶ Department of Urology, University of Minnesota, Minneapolis, MN, USA. dehm@umn.edu.

PMID: 40360904
DOI: 10.1038/s43018-025-00959-6

CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer

Jacob J Orme et al. Nat Cancer. 2025 May.

. 2025 May;6(5):740-742.

doi: 10.1038/s43018-025-00959-6.

Authors

Jacob J Orme¹, Emmanuel S Antonarakis^{2

3}, Scott M Dehm^{4

5

6}

Affiliations

¹ Department of Oncology, Mayo Clinic, Rochester, MN, USA.
² Division of Hematology, Oncology and Transplantation, University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA.
³ Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
⁴ Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. dehm@umn.edu.
⁵ Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. dehm@umn.edu.
⁶ Department of Urology, University of Minnesota, Minneapolis, MN, USA. dehm@umn.edu.

PMID: 40360904
DOI: 10.1038/s43018-025-00959-6

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: E.S.A. is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, Eli Lilly, Bayer, AstraZeneca, Bristol Myers Squibb, Clovis, Merck, Curium, Blue Earth Diagnostics, Foundation Medicine, Exact Sciences and Invitae; has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Bristol Myers Squibb, Bayer, AstraZeneca, Clovis and Merck; and is the co-inventor of a patented AR-V7 biomarker technology that has been licensed to Qiagen. J.J.O. receives research support from the National Cancer Institute (K12 CA90628-23) and the Prostate Cancer Foundation and previously received support from Genentech, Partner Therapeutics and NaNotics. S.M.D. has served as a paid consultant/advisor to Janssen, Bristol Myers Squibb and Oncternal Therapeutics and as principal investigator on grants awarded to the University of Minnesota by Janssen and Pfizer/Astellas.

References

1. Barbieri, C. E. et al. Nat. Genet. 44, 685–689 (2012). - DOI - PubMed - PMC
1. An, J., Wang, C., Deng, Y., Yu, L. & Huang, H. Cell Rep. 6, 657–669 (2014). - DOI - PubMed - PMC
1. Shi, L. et al. Cancer Res. 13, 3593–3606 (2021). - DOI
1. Boysen, G. et al. Clin. Cancer Res. 24, 5585–5593 (2018). - DOI - PubMed - PMC
1. Cavalcante, L. et al. Clin. Oncol. Precision Oncol. 7, e2300088 (2023). - DOI

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer

Affiliations

CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer

Authors

Affiliations

Conflict of interest statement

Similar articles

References

LinkOut - more resources

Full Text Sources